REGENXBIO Inc

For the period ended Dec 31, 2023. Filed Feb 27, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 27, 2024

RGNX$8.07+5.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Signatures

Pursuant to the requirements of Section 13 and 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on February 27, 2024.

REGENXBIO INC.
By:	/s/ Kenneth T. Mills
	Kenneth T. Mills,President and Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Allan M. Fox
Signature	Title	Date
/s/ Kenneth T. Mills	President, Chief Executive Officer and	February 27, 2024
Kenneth T. Mills	Director (Principal Executive Officer)
/s/ Vittal Vasista	Chief Financial Officer	February 27, 2024
Vittal Vasista	(Principal Financial and Accounting Officer)
/s/ Allan M. Fox	Chairman of the Board of Directors	February 27, 2024
/s/ Jean Bennett	Director	February 27, 2024
Jean Bennett
/s/ Alexandra Glucksmann	Director	February 27, 2024
Alexandra Glucksmann
/s/ A.N. “Jerry” Karabelas	Director	February 27, 2024
A.N. “Jerry” Karabelas
/s/ George Migausky	Director	February 27, 2024
George Migausky
/s/ David C. Stump	Director	February 27, 2024
David C. Stump
/s/ Daniel Tassé	Director	February 27, 2024
Daniel Tassé
/s/ Jennifer Zachary	Director	February 27, 2024
Jennifer Zachary

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.